{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":15,"n_cols":5,"rows_kept":15,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[13,2,13,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910787591103321"]
[null,null,"Titolo",null,"Current & emerging treatments for immune thrombocytopenia / / editor, Abdulgabar Salama"]
[null,null,"Pubbl/distr/stampa",null,"London, England : , : Future Medicine Ltd., , [2013]"]
[{"$nulls":4},"©2013"]
[null,null,"ISBN",null,"1-78084-195-7"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (135 p.)"]
[null,null,"Disciplina",null,"616.157"]
[null,null,"Soggetti",null,"Thrombocytopenia"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,"Nota di contenuto",null,"Title page; Copyright form; Contents; Foreword. Addressing current treatment options for autoimmune thrombocytopenia; 1. Pathogenesis; 2. Symptoms and diagnosis; 3. Treatment guidelines & algorithm; 4. Steroids; 5. Immunoglobulins; 6. Immunosuppressants; 7. Thrombopoietin receptor agonists; 8. Platelet transfusion; 9. Surgical approach; Index"]
[null,null,null,"Sommario/riassunto","Immune thrombocytopenia (ITP) is the best characterized human autoimmune disease and affects approximately 5% of the world's population. Clinically, it is defined by a low platelet count and increased bleeding risk. In this book, international experts provide a rounded overview of the disease and its management."]